Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pharmacological Approaches to Nonalcoholic Fatty Liver Disease: Current and Future Therapies
Idoia Genua, Kenneth Cusi
Diabetes Spectrum (2024) Vol. 37, Iss. 1, pp. 48-58
Open Access | Times Cited: 29

Showing 1-25 of 29 citing articles:

Role of Insulin Resistance in the Development of Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: From Bench to Patient Care
Juan Patricio Nogueira, Kenneth Cusi
Diabetes Spectrum (2024) Vol. 37, Iss. 1, pp. 20-28
Open Access | Times Cited: 46
Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD
Diana Barb, Srilaxmi Kalavalapalli, Eddison Godinez Leiva, et al.
Journal of Hepatology (2025)
Open Access | Times Cited: 4
Altered Mitochondrial Function in MASLD: Key Features and Promising Therapeutic Approaches
Tatjana Radosavljević, Milica Branković, Janko Samardžić, et al.
Antioxidants (2024) Vol. 13, Iss. 8, pp. 906-906
Open Access | Times Cited: 14
Practical Lifestyle Management of Nonalcoholic Fatty Liver Disease for Busy Clinicians
Shira Zelber‐Sagi, J. Bernadette Moore
Diabetes Spectrum (2024) Vol. 37, Iss. 1, pp. 39-47
Open Access | Times Cited: 9
Cardiovascular-Liver-Metabolic Health: Recommendations in Screening, Diagnosis, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease in Cardiovascular Disease via Modified Delphi Approach
Nicholas Chew, Anurag Mehta, Rachel Sze Jen Goh, et al.
Circulation (2024) Vol. 151, Iss. 1, pp. 98-119
Closed Access | Times Cited: 9
The Triad of Risk: Linking MASLD, Cardiovascular Disease and Type 2 Diabetes; From Pathophysiology to Treatment
Eleni Michalopoulou, J Thymis, Stamatios Lampsas, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 2, pp. 428-428
Open Access | Times Cited: 1
Reviewing MAESTRO-NASH and the implications for hepatology and health systems in implementation/accessibility of Resmetirom
Paul Brennan, Christopher J. Kopka, Leire Agirre-Garrido, et al.
npj gut and liver. (2025) Vol. 2, Iss. 1
Open Access | Times Cited: 1
Clinical Assessment of Common Medications for Nonalcoholic Fatty Liver Disease: A Systematic Review and Bayesian Network Meta‐Analysis
Rui Shi, Keyan Chai, Haojia Wang, et al.
Journal of Evidence-Based Medicine (2025) Vol. 18, Iss. 1
Open Access | Times Cited: 1
Linking Cardiovascular Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): The Role of Cardiometabolic Drugs in MASLD Treatment
Marios Zisis, Maria Chondrogianni, Θεόδωρος Ανδρουτσάκος, et al.
Biomolecules (2025) Vol. 15, Iss. 3, pp. 324-324
Open Access | Times Cited: 1
Nonalcoholic Fatty Liver Disease in Diabetes: A Call to Action
Kenneth Cusi
Diabetes Spectrum (2024) Vol. 37, Iss. 1, pp. 5-7
Open Access | Times Cited: 7
Making Sense of the Nonalcoholic Fatty Liver Disease Clinical Practice Guidelines: What Clinicians Need to Know
Kenneth Cusi, Jeff Budd, Eric L. Johnson, et al.
Diabetes Spectrum (2024) Vol. 37, Iss. 1, pp. 29-38
Open Access | Times Cited: 5
Guideline-based management of metabolic dysfunction-associated steatotic liver disease in the primary care setting
Alina M. Allen, Michael Charlton, Kenneth Cusi, et al.
Postgraduate Medicine (2024) Vol. 136, Iss. 3, pp. 229-245
Open Access | Times Cited: 5
Interdisciplinary perspectives on the co-management of metabolic dysfunction-associated steatotic liver disease and coronary artery disease
Jacob J. Gries, Jeffrey V. Lazarus, Paul Brennan, et al.
˜The œLancet. Gastroenterology & hepatology (2024) Vol. 10, Iss. 1, pp. 82-94
Closed Access | Times Cited: 4
Nonlinear relationship between hepatic steatosis index and reversion to normal glucose regulation in Chinese adults with prediabetes
Haiyong Zeng, Fei Yu, Haofei Hu, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
The Many Facets of PPAR-γ Agonism in Obesity and Associated Comorbidities: Benefits, Risks, Challenges, and Future Directions
Dimitris Kounatidis, Natalia G. Vallianou, Eleni Rebelos, et al.
Current Obesity Reports (2025) Vol. 14, Iss. 1
Closed Access
Role of anti-diabetic medications in the management of MASLD
Scott Isaacs, Fiona V Farrelly, Paul Brennan
Frontline Gastroenterology (2025), pp. flgastro-102856
Closed Access
A Comprehensive Review of Metabolic Dysfunction-Associated Steatotic Liver Disease: Its Mechanistic Development Focusing on Methylglyoxal and Counterbalancing Treatment Strategies
Izabela Berdowska, M. Matusiewicz, Izabela Fecka
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 6, pp. 2394-2394
Open Access
Therapeutic Potential of GLP-1 Receptor Agonists in Metabolic Associated Steatotic Liver Disease
Klaudia Nowak, Krzysztof Łupina, Anna Romac, et al.
Annals of Pharmacotherapy (2025)
Closed Access
Investigating the Effects of Gossypetin on Liver Health in Diet-Induced Pre-Diabetic Male Sprague Dawley Rats
Karishma Naidoo, Andile Khathi
Molecules (2025) Vol. 30, Iss. 8, pp. 1834-1834
Open Access
Strategic interventions in clinical randomized trials for metabolic dysfunction-associated steatotic liver disease (MASLD) and obesity in the pediatric population: a systematic review with meta-analysis and bibliometric analysis
Isabel Omaña‐Guzmán, Marisol Rosas‐Díaz, Yoscelina Estrella Martínez-López, et al.
BMC Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 3
Nonalcoholic steatohepatitis/metabolic dysfunction–associated steatohepatitis emerging market: Preparing managed care for early intervention, equitable access, and integrating the patient perspective
Bridget Flavin
Journal of Managed Care & Specialty Pharmacy (2024) Vol. 30, Iss. 9-a Suppl, pp. S1-S13
Closed Access | Times Cited: 2
Detecting altered hepatic lipid oxidation by MRI in an animal model of MASLD
Marc McLeod, Mario C. Chang, Anna Rushin, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 9, pp. 101714-101714
Open Access | Times Cited: 2
Screening of Lipid-Reducing Activity and Cytotoxicity of the Exometabolome from Cyanobacteria
Rúben Luz, Rita Cordeiro, Vítor Gonçalves, et al.
Marine Drugs (2024) Vol. 22, Iss. 9, pp. 412-412
Open Access | Times Cited: 1
Benefits of combining SGLT2 inhibitors and pioglitazone on risk of MASH in type 2 diabetes—A real‐world study
Chi‐Ho Lee, David Tak Wai Lui, Lung‐Yi Mak, et al.
Diabetes Obesity and Metabolism (2024) Vol. 27, Iss. 2, pp. 574-582
Closed Access | Times Cited: 1
The Pan-PPAR Agonist Lanifibranor Reverses Metabolic Dysfunction in People with Type 2 Diabetes and MASLD: A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial
Diana Barb, Srilaxmi Kalavalapalli, Eddison Godinez Leiva, et al.
(2024)
Closed Access
Page 1 - Next Page

Scroll to top